



## UNIVERSIDADE ESTADUAL DE CAMPINAS SISTEMA DE BIBLIOTECAS DA UNICAMP REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP

Versão do arquivo anexado / Version of attached file:

Versão do Editor / Published Version

Mais informações no site da editora / Further information on publisher's website:

https://www.sciencedirect.com/science/article/pii/S0303846722003869

DOI: https://doi.org/10.1016/j.clineuro.2022.107505

Direitos autorais / Publisher's copyright statement:

©2022 by Elsevier. All rights reserved.

ELSEVIER

Contents lists available at ScienceDirect

### Clinical Neurology and Neurosurgery

journal homepage: www.elsevier.com/locate/clineuro





### Factors associated with post-stroke depression in the acute phase of ischemic stroke: A cross-sectional study

Stefany Elias <sup>a,\*,1</sup>, Maria Luiza Benevides <sup>b</sup>, André Luiz Pereira Martins <sup>c</sup>, Gladys Lentz Martins <sup>c</sup>, Ana Beatriz Sperb Wanderley Marcos <sup>d</sup>, Jean Costa Nunes <sup>e,f,2</sup>

- <sup>a</sup> University of Southern Santa Catarina, Palhoça, Santa Catarina, Brazil
- <sup>b</sup> Child Neurology Department of University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
- <sup>c</sup> Neurology Department of Hospital Governador Celso Ramos (HGCR), Florianópolis, Santa Catarina, Brazil
- d Department of Medical Sciences, Hospital Polydoro Ernani de São Thiago, Federal University of Santa Catarina (UFSC), Santa Catarina, Brazil
- e Department of Pathology, Federal University of Santa Catarina (UFSC), Santa Catarina, Brazil
- <sup>f</sup> Neurodiagnostic Brasil, Diagnósticos em Neuropatologia, Florianópolis, Santa Catarina, Brazil

#### ARTICLE INFO

# Keywords: Post-stroke depression Stroke Depression COVID-19

#### ABSTRACT

*Objectives*: Ischemic stroke is a remarkable cause of death and disability worldwide. Post-stroke depression (PSD) is the most common psychiatric disturbance after stroke. Despite PSD being a potentially treatable condition, it still requires approaches to improve the early diagnosis. The present study aims to investigate the factors associated and correlated variables associated with PSD during hospitalization.

Materials and methods: A retrospective cross-sectional study was conducted in a specialized center of neurology in Santa Catarina, Brazil. 148 patients with acute ischemic stroke hospitalized between January 2020 and February 2021 were included. Sociodemographic, clinical and radiological variables were assessed during hospitalization. The Hospital Anxiety and Depression Scale (HADS) was applied, as well as the National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). Factors associated were investigated through binary logistic regression and continuous variables through correlation tests.

Results: The prevalence of PSD during hospitalization was 31.1%. Factors associated with PSD in the acute phase of the stroke were female sex (OR: 2.6; CI 95%: 1.3–5.4; p < 0.01) and post-stroke anxiety during hospitalization (OR: 4.9; CI 95%: 2.3–10.3; p < 0.01). The variables NIHSS, mRS, and stroke area were positively correlated with HADS – depression values.

Conclusions: This research evidenced a high prevalence of PSD in the acute phase of stroke. Despite the study being conducted during the COVID-19 pandemic, the frequency is similar to the non-pandemic periods. The research provided clues to identify and timely treat patients at greater risk of developing PSD during hospitalization.

#### 1. Introduction

Ischemic stroke is a vascular disorder responsible for the second leading cause of death in the world [1] and Brazil [2] and is an important determinant of dependency, poor quality of life, and disability [3]. Post-stroke depression (PSD) is the main psychiatric disorder after stroke, with a frequency of 34.7% three months after stroke [4] and about 25% one to five years after stroke in a metanalysis [5]. PSD

negatively impacts the patients' motor, functional and cognitive rehabilitation [6]. Despite being frequent and causing a significant burden of disease, PSD remains underdiagnosed and undertreated [6].

The main biological hypothesis for PSD is the hypothesis of the amines [7], especially serotonin, norepinephrine, and dopamine, which have reduced bioavailable concentrations due to disconnections in the ascending structures of the CNS due to ischemic injury [7]. Some studies regarding neuroimaging evaluation sought to identify specific areas

<sup>\*</sup> Correspondence to: Rua Dr. Percy João de Borba, No 238 Trindade, Florianópolis, Santa Catarina, Brazil.

E-mail addresses: stefyelias@hotmail.com (S. Elias), benevidesmarialuiza@gmail.com (M.L. Benevides), martinsandrelp@gmail.com (A.L.P. Martins), glentz63@gmail.com (G.L. Martins), anabeatrizsw@gmail.com (A.B.S.W. Marcos), jeanmedic@hotmail.com (J.C. Nunes).

<sup>1</sup> stefyelias@hotmail

<sup>&</sup>lt;sup>2</sup> jeanmedic@hotmail.com

related to the pathogenesis of depressive disorder after stroke, highlighting the prefrontal lobe, the frontal lobe, and the limbic system [7]. The precise pathophysiological mechanisms of PSD still need further investigation Fig. 1.

Studies related to risk factors for PSD identified pre-stroke depression as an important risk factor [8], as well as anxiety during hospitalization [8]. A study evaluated the impact of the diagnosis of PSD in the acute phase of stroke on the development of PSD three years after stroke and demonstrated a remarkable higher risk of fivefold [9]. It highlights the relevance of expending special attention to patients at major risk for PSD in the acute phase, which might impact the long-term recovery. Furthermore, other risk factors were identified regarding the severity aspects as well as the degree of disability after stroke evaluated by high modified Rankin Scale (mRS) and the National Institute of Health Stroke Scale (NIHSS) [10]. Another tool to quantify stroke severity can be performed utilizing radiological criteria such as measuring the stroke area, which has been used in limited studies.

Considering these aspects, the present study aimed to investigate the sociodemographic, clinical, and radiological profile of patients with acute ischemic stroke (AIS) admitted to a referral center for stroke treatment (Stroke-Unit of the Hospital Governador Celso Ramos -Stroke-Unit HGCR), to identify the prevalence of PSD during hospitalization and to elucidate the factors associated with this outcome. To our knowledge, this is the first cross-sectional study about PSD in the acute phase in Brazil during the COVID-19 pandemic.

#### 2. Methods

#### 2.1. Study design and setting

An observational, analytic, and cross-sectional study was carried out in a tertiary neurology service located in the Stroke-Unit HGCR, Florianopolis, Santa Catarina, Brazil.

#### 2.2. Participants and eligibility criteria

The participants were 148 patients with AIS of the anterior circulation who were consecutively admitted to the HGCR between January 2020 and January 2021.

The inclusion criteria were: 1) diagnosis of AIS in the frontal, temporal or parietal lobe confirmed in a neuroimaging exam (computed tomography [CT]; and/or magnetic resonance imaging, [MRI]) and 2) patients aged  $\geq$  15 years. The exclusion criteria were: 1) global aphasia, Wernicke aphasia, mixed transcortical and/or sensory transcortical

aphasia; 2) previous moderate to severe traumatic brain injury (TBI); 3) supratentorial brain tumors; 4) previous diagnosis of epilepsy; 5) medical history of severe cognitive deficit; 6) substance abuse disorder; 7) impaired level of consciousness (Glasgow Coma Scale < 9) during the first week of hospitalization and/or mechanical ventilation and/or 8) patients with cold symptoms.

#### 2.3. Sample size

The sample size was estimated using a previous regional study entitled "Assessment of the influence of the location of the motor and cognitive changes on the development of signs and symptoms of depression after stroke", carried out in southern Brazil ([Rider, C], unpublished data, 1994). The effect size estimated was 0.45 and using the chi-square test, with sample parameters of 10 degrees of freedom (df),  $\alpha$  (bilateral)  $=0.05, \ and \ \beta=0.20, \ a$  sample size of 81 patients was defined. Sixty patients were added to compensate for eventual losses, totaling 140 individuals.

#### 2.4. Variables and data collection

During the interview, the evaluated data were age in years, sex, self-referred skin color, years of education, marital status, history of hypertension, diabetes mellitus, other previous comorbidities, history of smoking, and alcoholism. During the neurological examination, the NIHSS and the mRS were applied to assess stroke severity. The hospital's electronic database included the TOAST etiological classification, presence or absence of hemorrhagic transformation, thrombolysis, and/or thrombectomy therapy.

The HADS (Hospital Anxiety and Depression Scale) was used to assess depressive disorder and anxiety in patients hospitalized in a non-psychiatric service, at the bedside, up to seven days after admission. The Portuguese version of the scale has already been validated in Brazil [11] and those patients with PSD and post-stroke anxiety (PSA) [12]. HADS has 2 subscales HADS-A for anxiety and HADS-D for depression. Each subscale has 7 items, each item ranging in score from 0 to 3 [13]. The cutoff point widely used for the general population is eight [13], and this value was used in the present study. Mild depression was determined with HADS-D ranging from 8 to 10, moderate depression from 11 to 14 points, and severe depression  $\geq$  15 points [14].

The neuroimaging exams (cranial CT and/or MRI) were evaluated to determine the specific territory of the ischemic lesion based on the anatomical limits of each lobe. The posterior limit of the frontal lobe was the central sulcus, and the inferior limit was the lateral sulcus [15]. The




Fig. 1. Representation of the incidence of hospitalizations due to acute ischemic stroke between January 2020 and January 2021 (black line). The dashed line represents the incidence of post-stroke depression during hospitalization in the same period and the dotted line represents the average of the HADS-D during hospitalization. The blue graphic demonstrates the incidence of COVID-19 cases in Brazil, during the same period.

parietal lobe was defined by the central sulcus anteriorly, the lateral sulcus laterally, and the imaginary line between the preoccipital notch and the parieto-occipital fissure posteriorly [15]. The temporal lobe limits were determined superiorly by the lateral sulcus and, posteriorly, by the imaginary line between the preoccipital notch and the parieto-occipital fissure [15]. The insula lobe is limited laterally by the basal ganglia, and medially by the labia of the lateral sulcus [15]. The basal ganglia are located medially to the lobe of the insula and laterally to the thalamus [15]. Furthermore, the exams were analyzed using the WEASIS Medical Viewer program, to perform the area calculation of the lesion in an axial section, considering the largest area in mm<sup>2</sup>.

Data were obtained by a medical professional researcher with certification to apply the questionnaire and experience in performing the neurological examination and the process of the data acquisition.

#### 2.5. Data analysis

Data were analyzed using the SPSS 20.0 program and described as relative and absolute frequencies. The magnitude of the association between the dependent variable and the independent variables was measured through the Odds Ratio (OR), with "p" values considered statistically significant when p < 0.05. The association between the categorical variables and depression during hospitalization was investigated using a binary logistic regression model. The continuous variables were evaluated using correlation tests (Kendall's Tau-b Test for non-parametric variables and Spearman's Test for ordinal variables). Furthermore, the categorical variables associated with depressive symptoms during hospitalization were included in a multiple logistic regression model. In addition, multivariate linear regression was performed to evaluate the continuous variables associated with the outcome (HADS-D score). Data were described in "R", "R square", and "p" values.

#### 2.6. Ethical considerations

This study was approved by the Ethics Committee of the HGCR (registration number: 3.794.456) and agreed with the Declaration of Helsinki. Informed consent was obtained from all patients and their anonymity was preserved.

#### 3. Results

We interviewed 148 patients with AIS admitted to the Stroke-Unit HGCR between January 2020 and February 2021. Among the 148 participants, 79 (53.4%) were male and the mean age was 64.5 years (SD  $\pm$  13.8). The prevalence of PSD in the hospitalization was 31.1%, while PSA was 33.8%. Among the 46 patients with depressive disorder, 26 (56.5%) had mild depression, 12 (26.1%) had moderate depression, and eight (17.4%) had severe depression.

About clinical variables, 70.9% of the patients had hypertension and 30.4% had diabetes mellitus. In addition, 40 (27%) of the participants consumed alcohol and 38 (25.7%) were smokers. Concerning the radiological variables, the right hemispheric was affected in 54.7% of the patients and the main affected topographies were the basal nuclei in 52% and the parietal lobe in 44.6% of the cases. The frequencies of stroke etiologies by TOAST classification were stroke of undetermined etiology in 32.4%; large-artery atherosclerosis in 25.7%; cardioembolism in 24.3%; small-vessel occlusion in 9.5% and stroke of other determined etiology in 8.1%. Regarding the therapeutic variables, 15.5% of the patients underwent intravenous thrombolysis and 9.5% underwent mechanical thrombectomy. About the degree of dependence of patients, 31.8% had a mRS score of 0%, and 26.4% had mRS score of 4. Table 1 shows the sociodemographic, clinical, radiological, and therapeutic data of the participants.

 ${\color{blue} \textbf{Table 2} shows the factors associated with PSD during hospitalization evaluated in a binary logistic regression model. The sociodemographic and the property of t$ 

**Table 1**Sociodemographic, clinical, and radiological features of patients with acute ischemic stroke hospitalized at the Stroke-Unit HGCR (Santa Catarina, Brazil).

Sex         79         \$3.4           Male         69         46.6           Female         Ethnicity         30         20.3           No-white         118         79.7           White         118         79.7           Marital status         27         18.2           Single         62         41.9           Married         26         17.6           Widower         33         22.3           Other         30         20.3           Psychiatric disorder during hospitalization         46         31.1           Depression         50         33.8           Anxiety         27         18.2           Both         7         7           Previous depressive disorder         118         79.7           No         30         20.3           Yes         118         79.7           Previous anxiety disorder         135         91.2           No         13         8.8           Yes         4         4         4.2           Lesion topography *         61         41.2         4.1           Frontal lobe         66         44.4         4.2	ischemic stroke hospitalized at the Stroke-U	nit HGCR (San	ta Catarina, Brazil).
Male         69         46.6           Female         Ethnicity         30         20.3           No-white         118         79.7           White         T         18.2           Marital status         27         18.2           Single         62         41.9           Married         26         17.6           Widower         33         22.3           Other         T         Provious differed during hospitalization         46         31.1           Depression         50         33.8         Anxiety         27         18.2           Both         T         77         18.2         18.2           Both         T         79.7         18.2	Categorical variables	n	%
Female	Sex	79	53.4
Ethnicity         30         20.3           No-white         118         79.7           White         Will           Marital status         27         18.2           Single         62         41.9           Married         26         17.6           Widower         33         22.3           Other         """"""""""""""""""""""""""""""""""""	Male	69	46.6
No.white   118	Female		
White         Image         62         41.9           Married         26         17.6           Widower         33         22.3           Other         Psychiatric disorder during hospitalization         46         31.1           Persession         50         33.8           Anxiety         27         18.2           Both         Fervious depressive disorder         118         79.7           No         30         20.3           Yes         Tervious anxiety disorder         135         91.2           No         13         8.8           Yes         Tervious anxiety disorder         135         91.2           No         13         8.8           Yes         Tervious anxiety disorder         13         8.8           Previous anxiety disorder         135         91.2         1.2           No         13         8.8         8           Yes         Tertical lobe         66         44.6         44.6           Parietal lobe         45         30.4         1.1         2.1         1.1         1.1         1.1         1.1         1.1         1.1         1.1         1.1         1.1         1.1	•		
Marital status         27         18.2           Single         62         41.9           Married         26         17.6           Widower         33         22.3           Other         T           Psychiatric disorder during hospitalization         46         31.1           Depression         50         33.8           Anxiety         27         18.2           Both         T         77           Previous depressive disorder         118         79.7           Both         T         79.7           Previous anxiety disorder         135         91.2           No         30         20.3           Yes         13         8.8           Previous anxiety disorder         135         91.2           No         13         8.8           Yes         12         12           Previous anxiety disorder         135         91.2           No         13         8.8           Yes         46         41.6           Previous anxiety disorder         135         91.2           Rorial disorder during hospitalization         77         52.0           Basal ganglia		118	79.7
Single         62         41,9           Married         26         17.6           Widower         33         22.3           Other         ************************************		27	10.0
Married         26         17.6           Wildower         33         22.3           Other         "           Psychiatric disorder during hospitalization         46         31.1           Depression         50         33.8           Anxiety         27         18.2           Both         "         ***           Previous depressive disorder         118         79.7           No         30         20.3           Yes         "         ***           Previous anxiety disorder         135         91.2           No         13         8.8           Yes         ***         ***           Lesion topography *         61         41.2           Frontal lobe         66         44.6           Parietal lobe         51         34.5           Forntal lobe         45         30.4           Insular lobe         77         52.0           Basal ganglia         ***         ***           Hemisphere affected ***         77         52.0           Left         81         54.7           Right         10         6.8           Both         ****         ***			
Widower         33         22.3           Other         ************************************	9		
Psychiatric disorder during hospitalization         46         31.1           Depression         50         33.8           Anxiety         27         18.2           Both         ************************************			
Depression	Other		
Anxiery Both Previous depressive disorder No	Psychiatric disorder during hospitalization	46	31.1
Both	=		
Previous depressive disorder No Yes  Previous anxiety disorder No 13 8.8 Yes  Lesion topography * Lesion	· · · · · · · · · · · · · · · · · · ·	27	18.2
No       30       20.3         Yes          Previous anxiety disorder       135       91.2         No       13       8.8         Pres           Lesion topography *       61       41.2         Frontal lobe       66       44.6         Parietal lobe       51       34.5         Temporal lobe Insular lobe       77       52.0         Basal ganglia           Hemisphere affected **       77       52.0         Left       81       54.7         Right       10       6.8         Both           Hemorrhagic transformation       126       85.1         No       22       14.9         Yes           Previous stroke       100       67.6         No       48       32.4         Yes           Previous stroke       100       67.6         No       48       32.4         Yes           Grade 0       30       20.3         Grade 1       15       10.1 </td <td></td> <td>110</td> <td><b>50.5</b></td>		110	<b>50.5</b>
Yes         135         91.2           No         13         8.8           Yes         13         8.8           Lesion topography *         61         41.2           Frontal lobe         66         44.6           Parietal lobe         51         34.5           Temporal lobe         45         30.4           Insular lobe         77         52.0           Basal ganglia         77         52.0           Hemisphere affected **         77         52.0           Left         81         54.7           Right         10         6.8           Both         81         54.7           Hemorrhagic transformation         126         85.1           No         22         14.9           Yes         7         52.0           Previous stroke         100         67.6           No         48         32.4           Yes         7         31.8           Grade 0         30         20.3           Grade 1         15         10.1           Grade 2         14         9.5           Grade 3         39         26.4           Grad			
Previous anxiety disorder         135         91.2           No         13         8.8           Yes         13         8.8           Lesion topography *         61         41.2           Frontal lobe         66         44.6           Parietal lobe         45         30.4           Image and particular lobe         77         52.0           Basal ganglia         Fremporal lobe         45         30.4           Hemisphere affected **         77         52.0         52.0           Left         81         54.7         81.8           Right         10         6.8         85.1         6.8         85.1         80.0         80.0         85.1         80.0		30	20.3
No Yes  Lesion topography * 61 41.2  Frontal lobe 66 44.6  Parietal lobe 51 34.5  Temporal lobe 45 30.4  Insular lobe 77 52.0  Basal ganglia  Hemisphere affected ** 77 52.0  Left 81 54.7  Right 10 6.8  Both  Hemorrhagic transformation 126 85.1  No 22 14.9  Yes  Previous stroke 100 67.6  No 48 32.4  Yes  mBS³ *** 47 31.8  Grade 0 30 20.3  Grade 1 15 10.1  Grade 2 14 9.5  Grade 3 39 26.4  Grade 3 39 26.4  Grade 4 3 2.0  Grade 5  NIHSS³ tratified 96 64.9  ≤ 4 3.2  Crade 5  NIHSS³ tratified 96 64.9  ≤ 4 9.5  Intravenous thrombolysis 14 9.5  Intravenous thrombolysis 14 9.5  Mechanical thrombectomy  Comorbidities 105 70.9  Hypertension 45 30.4  Diabetes 40 27.0  Dyslipidemia  Alcohol consumption 108 73.0  No 40 27.0  Yes  Smoking 57 38.5  No 38 25.7  Current smoker 53 35.8  Ex-smoker  Continuous variables Median 1Q 25-75  Age 67 56.3 - 74  Time of hospitalization (days) 8 6 - 114  HADS-D³ during hospitalization 5 2 - 8  RIADS-D³ during hospitalization 5 3 - 8.8  Stroke area (mm²) 485 222.7 - 1401.4		135	91.2
Yes         Lesion topography *         61         41.2           Frontal lobe         66         44.6           Parietal lobe         51         34.5           Temporal lobe         45         30.4           Insular lobe         77         52.0           Basal ganglia         **           Hemisphere affected **         77         52.0           Left         81         54.7           Right         10         6.8           Both         **         **           Hemorrhagic transformation         126         85.1           No         22         14.9           Yes         **         **           Previous stroke         100         67.6           No         48         32.4           Yes         **         **           MRS****         47         31.8           Grade 0         30         20.3           Grade 1         15         10.1           Grade 2         14         9.5           Grade 3         39         26.4           > 4         52         35.1           Yes         **         **           Intra			
Frontal lobe Parietal lobe Parietal lobe Parietal lobe Fromporal lobe Insular lobe Insular lobe Basal ganglia Hemisphere affected **  Left Right Right Both Hemorrhagic transformation No 22 14.9 Yes Previous stroke Inou 67.6 No 48 32.4 Yes  BRS***  Grade 0 Grade 1 Grade 2 Grade 1 Grade 3 Grade 1 Grade 5 NIHSSb stratified Stratifi			
Parietal lobe         51         34.5           Temporal lobe         45         30.4           Insular lobe         77         52.0           Basal ganglia         ***           Hemisphere affected **         77         52.0           Left         81         54.7           Right         10         6.8           Both         ***         ***           Hemorrhagic transformation         126         85.1           No         22         14.9           Yes         ***         ***           Previous stroke         100         67.6           No         48         32.4           Yes         ***         ***           mRS³***         47         31.8           Grade 0         30         20.3           Grade 1         15         10.1           Grade 2         14         9.5           Grade 3         39         26.4           Grade 4         3         2.0           Grade 5         ***         ***           NIHSS¹* stratified         96         64.9           ≤ 4         52         35.1           Nechanical thrombecto	Lesion topography *	61	41.2
Temporal lobe         45         30.4           Insular lobe         77         52.0           Basal ganglia         77         52.0           Hemisphere affected **         77         52.0           Left         81         54.7           Right         10         6.8           Both             Hemorrhagic transformation         126         85.1           No         22         14.9           Yes             Previous stroke         100         67.6           No         48         32.4           Yes             mRS³ ***         47         31.8           Grade 0         30         20.3           Grade 1         15         10.1           Grade 2         14         9.5           Grade 3         39         26.4           Grade 4         3         2.0           Grade 5         NIHSSb* stratified         96         64.9           ≤ 4         52         35.1           > 4         7         9.5           Intravenous thrombolysis         14         9.5	Frontal lobe	66	44.6
Insular lobe   77   52.0	Parietal lobe	51	34.5
Basal ganglia   Hemisphere affected **   77   52.0     Left			
Hemisphere affected **       77       52.0         Left       81       54.7         Right       10       6.8         Both       T         Hemorrhagic transformation       126       85.1         No       22       14.9         Yes       T         Previous stroke       100       67.6         No       48       32.4         Yes       T       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       T       10.1         NIHSSb stratified       96       64.9         ≤ 4       52       35.1         > 4       1       9.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       40       27.0         Alcohol consumption       108       73.0         No <td></td> <td>77</td> <td>52.0</td>		77	52.0
Left       81       54.7         Right       10       6.8         Both       10       6.8         Hemorrhagic transformation       126       85.1         No       22       14.9         Yes       7       14.9         Previous stroke       100       67.6         No       48       32.4         Yes       3       32.4         mRS <sup>a</sup> ***       47       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       5       35.1         NHHSS <sup>b</sup> stratified       96       64.9         ≤ 4       52       35.1         > 4       52       35.1         Therapeutic approaches       13       15.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       Alcohol consumption	5 5	77	F2 0
Right Both       10       6.8         Hemorrhagic transformation       126       85.1         No       22       14.9         Yes       100       67.6         No       48       32.4         Yes       32.4       32.4         Yes       47       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       NIHSS <sup>b</sup> stratified       96       64.9         ≤ 4       52       35.1         ✓ 4       7       3.5         Intravenous thrombolysis       14       9.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       40       27.0         No       38       25.7         Smoking       57       38.5         No       38       25.7         Current smoker			
Hemorrhagic transformation   126   85.1     No   22   14.9     Yes			
Hemorrhagic transformation   126   85.1     No   22   14.9     Yes     Previous stroke   100   67.6     No   48   32.4     Yes     mRS <sup>a</sup> ***   47   31.8     Grade 0   30   20.3     Grade 1   15   10.1     Grade 2   14   9.5     Grade 3   39   26.4     Grade 4   3   2.0     Grade 5     NIHSS <sup>b</sup> stratified   96   64.9     ≤ 4   52   35.1     > 4     Therapeutic approaches   23   15.5     Intravenous thrombolysis   14   9.5     Mechanical thrombectomy     Comorbidities   105   70.9     Hypertension   45   30.4     Diabetes   40   27.0     Dyslipidemia     Alcohol consumption   108   73.0     No   40   27.0     Yes     Smoking   57   38.5     No   38   25.7     Current smoker   53   35.8     Ex-smoker     Continuous variables   Median   IQ 25-75     Age   67   56.3 - 74     Time of hospitalization   5   2 - 8     HADS-D <sup>c</sup> during hospitalization   5   3 - 8.8     Stroke area (mm <sup>2</sup> )   485   222.7 - 1401.4	=	10	0.0
No       22       14.9         Yes       100       67.6         No       48       32.4         Yes       78         mRS <sup>n</sup> ***       47       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       52       35.1         NHSS <sup>b</sup> stratified       96       64.9         ≤ 4       52       35.1         > 4       1       9.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       105       70.9         Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia         Alcohol consumption       108       73.0         No       40       27.0         Yes       5       38       25.7         Current smoker       53       35.8         Ex-smoker       53       35.8         Continuo		126	85.1
Previous stroke       100       67.6         No       48       32.4         Yes       3         mRS³ ***       47       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5           NIHSSb stratified       96       64.9         ≤ 4       52       35.1         > 4       52       35.1         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       105       70.9         Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       108       73.0         Alcohol consumption       108       73.0         No       38       25.7         Current smoker       53       35.8         Ex-smoker       53       35.8         Current smoker       53       35.8         Ex-smoker       67	=	22	14.9
No       48       32.4         Yes       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       Stristified       96       64.9         ≤ 4       52       35.1         > 4       52       35.1         Therapeutic approaches       23       15.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia         Alcohol consumption       108       73.0         No       40       27.0         Yes       Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       53       35.8         Ex-smoker       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-D <sup>6</sup> during hospi	Yes		
Yes         mRS³ ***       47       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       NIHSSb stratified       96       64.9         ≤ 4       52       35.1         > 4       1       9.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       4       73.0         Alcohol consumption       108       73.0         No       40       27.0         Yes       5       38.5         Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       5       3.8         Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days) <td< td=""><td></td><td></td><td></td></td<>			
mRS <sup>a</sup> ***       47       31.8         Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       Therapeutic stratified       96       64.9         ≤ 4       52       35.1         > 4       Therapeutic approaches       23       15.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       To.9       9.5         Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia         Alcohol consumption       108       73.0         No       40       27.0         Yes       Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       53       35.8         Ex-smoker       67       56.3 - 74         Time of hospitalization (days)       8       6-14         HADS-D <sup>c</sup> during hospitalization<		48	32.4
Grade 0       30       20.3         Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       T         NIHSS <sup>b</sup> stratified       96       64.9         ≤ 4       52       35.1         > 4       52       35.1         Nether a contraction       14       9.5         Mechanical thrombolysis       14       9.5         Mechanical thrombectomy       45       30.4         Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia         Alcohol consumption       108       73.0         No       40       27.0         Yes         Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker         Continuous variables       Median       IQ 25–75         Age       67       56.3 – 74         Time of hospitalization (days)       8		477	01.0
Grade 1       15       10.1         Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5       Therabet Stratified       96       64.9         ≤ 4       52       35.1         > 4       52       35.1         > 4       1       9.5         Mechanical thrombolysis       14       9.5         Mechanical thrombectomy       105       70.9         Comorbidities       40       27.0         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       Alcohol consumption       108       73.0         No       40       27.0         Yes       Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       53       35.8         Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-P <sup>6</sup> during hospitalization       5       2 - 8			
Grade 2       14       9.5         Grade 3       39       26.4         Grade 4       3       2.0         Grade 5           NIHSS <sup>b</sup> stratified       96       64.9         ≤ 4       52       35.1         > 4           Therapeutic approaches       23       15.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy           Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia           Alcohol consumption       108       73.0         No       40       27.0         Yes           Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker           Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14			
Grade 4       3       2.0         Grade 5       Stratified       96       64.9         ≤ 4       52       35.1         > 4       Therapeutic approaches       23       15.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       Top       9.5         Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       Value       73.0         Alcohol consumption       108       73.0         No       40       27.0         Yes       Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       53       35.8         Ex-smoker       67       56.3 − 74         Time of hospitalization (days)       8       6 − 14         HADS-D <sup>c</sup> during hospitalization       5       2 − 8         HADS-A <sup>d</sup> during hospitalization       5       3 − 8.8         Stroke area (mm²)       485       222.7 − 1401.4			
Grade 5         NIHSS <sup>b</sup> stratified       96       64.9         ≤ 4       52       35.1         > 4	Grade 3	39	26.4
NIHSSb stratified       96       64.9         ≤ 4       52       35.1         > 4       52       35.1         Therapeutic approaches       23       15.5         Intravenous thrombolysis       14       9.5         Mechanical thrombectomy         Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       108       73.0         Alcohol consumption       108       73.0         No       40       27.0         Yes       Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       5       3.8         Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-Dc during hospitalization       5       2 - 8         HADS-Ad during hospitalization       5       3 - 8.8         Stroke area (mm²)       485       222.7 - 1401.4	Grade 4	3	2.0
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			
No			
Therapeutic approaches         23         15.5           Intravenous thrombolysis         14         9.5           Mechanical thrombectomy          70.9           Comorbidities         105         70.9           Hypertension         45         30.4           Diabetes         40         27.0           Dyslipidemia          73.0           No         40         27.0           Yes             Smoking         57         38.5           No         38         25.7           Current smoker         53         35.8           Ex-smoker             Continuous variables         Median         IQ 25-75           Age         67         56.3 - 74           Time of hospitalization (days)         8         6 - 14           HADS-D <sup>c</sup> during hospitalization         5         2 - 8           HADS-A <sup>d</sup> during hospitalization         5         3 - 8.8           Stroke area (mm²)         485         222.7 - 1401.4		52	35.1
Intravenous thrombolysis       14       9.5         Mechanical thrombectomy       70.9         Comorbidities       105       70.9         Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia       8       73.0         Alcohol consumption       108       73.0         No       40       27.0         Yes       57       38.5         Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker         Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-D <sup>c</sup> during hospitalization       5       2 - 8         HADS-A <sup>d</sup> during hospitalization       5       3 - 8.8         Stroke area (mm²)       485       222.7 - 1401.4		22	15.5
Mechanical thrombectomy         105         70.9           Comorbidities         105         30.4           Hypertension         45         30.4           Diabetes         40         27.0           Dyslipidemia         8         73.0           No         40         27.0           Yes         8         57         38.5           No         38         25.7           Current smoker         53         35.8           Ex-smoker         8         6.7           Continuous variables         Median         IQ 25-75           Age         67         56.3 - 74           Time of hospitalization (days)         8         6 - 14           HADS-D <sup>c</sup> during hospitalization         5         2 - 8           HADS-A <sup>d</sup> during hospitalization         5         3 - 8.8           Stroke area (mm²)         485         222.7 - 1401.4			
Comorbidities         105         70.9           Hypertension         45         30.4           Diabetes         40         27.0           Dyslipidemia             Alcohol consumption         108         73.0           No         40         27.0           Yes             Smoking         57         38.5           No         38         25.7           Current smoker         53         35.8           Ex-smoker             Continuous variables         Median         IQ 25-75           Age         67         56.3 - 74           Time of hospitalization (days)         8         6 - 14           HADS-P6 during hospitalization         5         2 - 8           HADS-Ad during hospitalization         5         3 - 8.8           Stroke area (mm²)         485         222.7 - 1401.4		11	5.0
Hypertension       45       30.4         Diabetes       40       27.0         Dyslipidemia           Alcohol consumption       108       73.0         No       40       27.0         Yes           Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker         Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-P <sup>6</sup> during hospitalization       5       2 - 8         HADS-A <sup>d</sup> during hospitalization       5       3 - 8.8         Stroke area (mm²)       485       222.7 - 1401.4		105	70.9
Dyslipidemia         Alcohol consumption       108       73.0         No       40       27.0         Yes       ***         Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       ****       ****         Continuous variables       ***Median       *****       *****         Age       67       56.3 - 74       ****         Time of hospitalization (days)       8       6 - 14         HADS-P <sup>6</sup> during hospitalization       5       2 - 8         HADS-A <sup>d</sup> during hospitalization       5       3 - 8.8         Stroke area (mm²)       485       222.7 - 1401.4			
Alcohol consumption       108       73.0         No       40       27.0         Yes       7       38.5         Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       8       6.7         Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-D <sup>c</sup> during hospitalization       5       2 - 8         HADS-A <sup>d</sup> during hospitalization       5       3 - 8.8         Stroke area (mm²)       485       222.7 - 1401.4	Diabetes	40	27.0
No       40       27.0         Yes          Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker           Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-D <sup>c</sup> during hospitalization       5       2 - 8         HADS-A <sup>d</sup> during hospitalization       5       3 - 8.8         Stroke area (mm²)       485       222.7 - 1401.4			
Yes         Smoking       57       38.5         No       38       25.7         Current smoker       53       35.8         Ex-smoker       Wedian       IQ 25-75         Continuous variables       Median       IQ 25-75         Age       67       56.3 - 74         Time of hospitalization (days)       8       6 - 14         HADS-D <sup>c</sup> during hospitalization       5       2 - 8         HADS-A <sup>d</sup> during hospitalization       5       3 - 8.8         Stroke area (mm²)       485       222.7 - 1401.4	*		
Smoking         57         38.5           No         38         25.7           Current smoker         53         35.8           Ex-smoker         ***         ***           Continuous variables         Median         IQ 25-75           Age         67         56.3 - 74           Time of hospitalization (days)         8         6 - 14           HADS-P <sup>c</sup> during hospitalization         5         2 - 8           HADS-A <sup>d</sup> during hospitalization         5         3 - 8.8           Stroke area (mm²)         485         222.7 - 1401.4		40	27.0
No         38         25.7           Current smoker         53         35.8           Ex-smoker         Continuous variables         Median         IQ 25-75           Age         67         56.3 - 74           Time of hospitalization (days)         8         6 - 14           HADS-P <sup>6</sup> during hospitalization         5         2 - 8           HADS-A <sup>d</sup> during hospitalization         5         3 - 8.8           Stroke area (mm²)         485         222.7 - 1401.4		F.7	20 5
Current smoker         53         35.8           Ex-smoker         Wedian         IQ 25-75           Age         67         56.3 - 74           Time of hospitalization (days)         8         6 - 14           HADS-P <sup>c</sup> during hospitalization         5         2 - 8           HADS-A <sup>d</sup> during hospitalization         5         3 - 8.8           Stroke area (mm²)         485         222.7 - 1401.4	=		
Ex-smoker         Median         IQ 25–75           Age         67         56.3 – 74           Time of hospitalization (days)         8         6 – 14           HADS-D <sup>c</sup> during hospitalization         5         2 – 8           HADS-A <sup>d</sup> during hospitalization         5         3 – 8.8           Stroke area (mm²)         485         222.7 – 1401.4			
Continuous variablesMedianIQ 25-75Age $67$ $56.3 - 74$ Time of hospitalization (days) $8$ $6 - 14$ HADS-D <sup>c</sup> during hospitalization $5$ $2 - 8$ HADS-A <sup>d</sup> during hospitalization $5$ $3 - 8.8$ Stroke area (mm²) $485$ $222.7 - 1401.4$		55	55.5
Age $67$ $56.3 - 74$ Time of hospitalization (days) $8$ $6 - 14$ HADS-D <sup>c</sup> during hospitalization $5$ $2 - 8$ HADS-A <sup>d</sup> during hospitalization $5$ $3 - 8.8$ Stroke area (mm²) $485$ $222.7 - 1401.4$		Median	IQ 25-75
Time of hospitalization (days)8 $6-14$ HADS-Pc during hospitalization5 $2-8$ HADS-Ad during hospitalization5 $3-8.8$ Stroke area (mm²)485 $222.7-1401.4$			
$A^{d}$ during hospitalization 5 3 - 8.8 Stroke area (mm²) 485 222.7 - 1401.4		8	6 - 14
Stroke area (mm²) 485 222.7 – 1401.4			
3 1-0			
	1411100	J	1 - 0

HGCR - Hospital Governador Celso Ramos

<sup>&</sup>lt;sup>a</sup> mRS – modified Rankin scale

<sup>&</sup>lt;sup>b</sup> NIHSS -National Institutes of Health Stroke Scale

 $<sup>^{</sup>c}$  HADS-D – Hospital Anxiety and Depression Scale - Depression

<sup>&</sup>lt;sup>d</sup> HADS-A – Hospital Anxiety and Depression Scale - Anxiety

- \* Some patients had lesions in more than one topography
- \*\* Some patients had lesions in both hemispheres
- \*\*\* In-hospital mRS up to 7 days after admission

variables age, ethnicity, and marital status were not associated with intrahospital PSD. The female sex demonstrated to be an important factor associated with PSD (OR: 2.6; CI 95%: 1.3–5.4; p < 0.01), as well as PSA during hospitalization (OR: 4.9; CI 95%: 2.3–10.3; p < 0.01). Furthermore, anxiety before hospitalization was associated with depression during hospitalization (OR: 2.3; CI 95%: 1.04–5.4; p 0.04). In addition, the presence of hemorrhagic transformation in neuroimaging was shown to be a factor associated with PSD (OR: 2.6; CI 95%: 1.03–6.5; p 0.04). Variables that evaluate stroke severity such as NIHSS and stroke area were not shown to be associated with PSD. Parietal lobe injury was associated with PSD, behaving as a protective factor (OR: 0.3; CI 95%: 0.2–0.7; p < 0.01), as well as the previous diagnosis of hypertension (OR: 0.4; CI 95%: 0.2–0.9; p 0.03).

The variables associated with the outcome were included in a multiple logistic regression model. The variables sex (p = 0.04), anxiety symptoms during hospitalization (p < 0.01), previous diagnosis of hypertension (p = 0.02) and parietal lobe involvement (p < 0.01) remained independently associated with depression symptoms during hospitalization. Furthermore, in the multivariate linear regression model that included the continuous variables of Table 2, only HADS-A score during hospitalization remained independently associated with HADS-D score during hospitalization (p < 0.01).

Table 3 evidence the correlation tests between sociodemographic, clinical, laboratory and radiological variables and the HADS-D values during hospitalization. The clinical variables HADS-A values during hospitalization (R: 0.32;  $R^2$ : 0.1024; p < 0.01), NIHSS (R: 0.22;  $R^2$ : 0.0484; p < 0.01) and mRS (R: 0.33;  $R^2$ : 0.1089; p < 0.01) were positively correlated with HADS-D score. Furthermore, the radiological variable stroke area also demonstrated a positive correlation with the HADS-D score (R: 0.13;  $R^2$ : 0.0169; p < 0.01). Sociodemographic and laboratory variables were not correlated with HADS-D.

Graphic 1 demonstrates the incidence of hospital admissions for AIS in the Stroke-Unit HGCR from January 2020 to January 2021, as well as the incidence of PSD and the mean of the HADS-D scale in the same period. Also, the graphic represents the incidence of the cases of COVID-19 in Brazil between January 2020 and January 2021. The graphic shows a reduction in the incidence of AIS in April and September 2020 accompanied by an increase in the averages of HADS-D in the same period.

#### 4. Discussion

The present research evidenced a high frequency of PSD during hospitalization for AIS in the period of the study. Female sex and anxiety during hospitalization were identified as strong factors associated with depression during hospitalization. Interestingly, the parietal lobe and previous history of hypertension behaved as a protective factor for the development of PSD during hospitalization. Finally, the NIHSS, mRS, and stroke area were positively correlated with HADS-D in the acute phase of the stroke. To our knowledge, this is the first cross-sectional study about PSD in the acute phase of the ischemic stroke conducted in the COVID-19 pandemic.

The high frequency of PSD identified in the present study is in agreement with the current literature, as rated on a German study that identified a frequency of 31.1% in the early weeks after stroke (median: 6 weeks) [16]. Another study carried out in Australia determined a frequency of 20% 12 months after stroke [17] and one Brazilian study identified a prevalence of 20% after one-to-three months after stroke using 11 as the cutoff point to determine depression by the HADS-D [18]. A meta-analysis that included 61 studies by Hackett et al. evidenced a frequency of 31% at any time up to five years after stroke [5].

Research conducted in Saudi Arabia during the COVID-19 pandemic

**Table 2**Predictors of post-stroke depression during hospitalization in a binary logistic regressions analysis.

regressions analysis.				
Variables	HADS-D <sup>a</sup>	HADS-D <sup>a</sup>	OR	p
	< 8	≥ 8 N (0/)	(CI 95%)	value
h	N (%)	N (%)		
<b>Age</b> <sup>b</sup> Age ≤ 67 years	56 (70.9) 46 (67.7)	23 (29.1) 23 (33.3)	1.2 (0.6 – 2.4)	0.58
Age $\geq$ 67 years	40 (07.7)	23 (33.3)	2.4)	
Sex	62 (78.5)	17 (21.5)	2.6 (1.3 –	< 0.01
Male Female	40 (58)	29 (42)	5.4)	
Ethnicity	21 (70)	9 (30)	0.9 (0.4 –	0.89
No-white	81 (68.6)	37 (31.4)	2.2)	
White Marital status	54 (73)	20 (27)	1.5 (0.7 –	0.29
No	48 (64.9)	20 (27) 26 (35.1)	2.9)	0.29
Yes				
Anxiety <sup>c</sup> disorder during hospitalization	79 (80.6) 23 (46)	19 (19.4) 27 (54)	4.9 (2.3 – 10.3)	< 0.01
No	23 (40)	27 (34)	10.3)	
Yes				
Previous depressive disorder	85 (72) 17 (56.7)	33 (28) 13 (43.3)	1.2 (0.9 – 1.7)	0.08
No	17 (30.7)	10 (40.0)	1.7)	
Yes				
Previous anxiety disorder No	98 (72.6) 4 (30.8)	37 (27.4) 9 (69.2)	2.3 (1.04 – 5.4)	0.04
Yes	1 (30.0)	J (UJ.Z)	0.1)	
NIHSS <sup>d</sup> stratified	70 (72.9)	26 (27.1)	1.7 (0.8 –	0.16
$NIHSS^b \le 4$ $NIHSS^b > 4$	32 (61.5)	20 (38.5)	3.4)	
Previous stroke	65 (65)	35 (35)	0.6 (0.3 -	0.14
No	37 (77.1)	11 (22.9)	1.2)	
Yes Hemisphere affected	47 (70.1)	20 (29.9)	1.1 (0.6 –	0.70
Right hemisphere	55 (69.7)	26 (32.1)	2.3)	0.70
Left hemisphere	E0 (E4 ()	10 (05.4)	1700	0.15
Basal ganglia topography No	53 (74.6) 49 (73.6)	18 (25.4) 28 (36.4)	1.7 (0.8 – 3.4)	0.15
Yes	()	(===,	,	
Frontal lobe	62 (71.3)	25 (28.7)	1.3 (0.6 –	0.46
No Yes	40 (65.6)	21 (34.4)	2.6)	
Temporal lobe	68 (70.1)	29 (29.9)	1.2 (0.6 –	0.69
No Yes	34 (66.7)	17 (33.3)	2.4)	
Parietal lobe	48 (58.5)	34 (41.5)	0.3 (0.2 -	< 0.01
No	54 (81.8)	12 (18.2)	0.7)	
Yes Insular lobe	74 (71.8)	29 (28.2)	1.6 (0.7 –	0.11
No	28 (62.2)	17 (37.8)	3.2)	0.11
Yes	( 0)	0.00=43	. =	
Stroke area <sup>e</sup> Area ≤ 928 mm²	70 (72.9) 32 (61.5)	26 (27.1) 20 (38.5)	1.7 (0.8 – 3.4)	0.16
Area $> 928 \text{ mm}^2$	02 (01.0)	20 (00.0)	0.1)	
Previous hypertension	24 (55.8)	19 (44.2)	0.4 (0.2 –	0.03
No Yes	78 (74.3)	27 (25.7)	0.9)	
Previous diabetes	69 (67)	34(33)	0.7 (0.3 –	0.44
No Yes	33 (73.3)	12 (26.7)	1.6)	
Intravenous thrombolysis	87 (69.6)	38 (30.4)	1.2 (0.5 –	0.68
No	15 (65.2)	8 (34.8)	3.1)	
Yes Mechanical thrombectomy	95 (70.9)	39 (29.1)	2.4 (0.8 –	0.11
No	7 (50)	7 (50)	7.4)	0.11
Yes				
Hemorrhagic transformation	91 (72.2) 11 (50)	35 (27.8) 11 (50)	2.6 (1.03 – 6.5)	0.04
No	11 (00)	11 (50)	0.0)	
Yes	<b>50</b> 444 ***	07 (00 ::	0.6.00.6	0.00
Current smoke No	73 (66.4) 29 (76.3)	37 (33.6) 9 (23.7)	0.6 (0.3 – 1.4)	0.26
Yes	(, 0.0)	- (20.7)	/	
Alcohol consumption	74 (68.5)	34 (31.5)	0.9 (0.4 –	0.86
No Yes	28 (70)	12(30)	2.1)	

- <sup>a</sup> Hospital Anxiety and Depression Scale Depression ( $\geq$  8 points for depression)
- <sup>b</sup> Age was stratified by median
- <sup>c</sup> Hospital Anxiety and Depression Scale Anxiety (≥ 8 points for anxiety)
- <sup>d</sup> National Institute Health Stroke Scale
- e Stroke area was stratified by mean

**Table 3**Investigation of sociodemographic, clinical, laboratory and radiological continuous variables and the correlation with HADS-D during hospitalization.

continuous variables and the correlation with Thibb b during hospitalization.						
HADS-D during	Median	R	$\mathbb{R}^2$	p value		
hospitalization	(IQ 25 – 75)					
Sociodemographic variables						
Age <sup>a</sup>	67 (56.3 – 74)	-	0.0001	0.86		
		0.01				
Years of education <sup>a</sup>	6 (4 – 12.8)	-	0.0025	0.44		
		0.05				
Clinical variables						
Time of hospitalization in days <sup>a</sup>	8 (6–14)	0.08	0.0064	0.15		
HADS-A during hospitalization <sup>a</sup>	5 (3 – 8.8)	0.32	0.1024	< 0.01		
NIHSS <sup>a</sup>	3 (1-6)	0.22	0.0484	< 0.01		
mRS <sup>b</sup>	1 (0 – 4)	0.33	0.1089	< 0.01		
Laboratory variables						
LDLa	114 (92 - 139)	-	0.0025	0.42		
		0.05				
HDL <sup>a</sup>	43 (34-52)	0.04	0.0016	0.53		
HbA1C <sup>a</sup>	5.9 (5.6 – 7)	0.01	0.0001	0.86		
Radiological variable						
Stroke area <sup>a</sup>	485 (222.7 – 1401.4)	0.13	0.0169	0.02		

<sup>&</sup>lt;sup>a</sup> Kendall's Tau b correlation was used.

evidenced an elevated frequency (36%) of PSD 90 days after stroke [19], similar data to that observed in previous studies in the non-pandemic period [5,16]. Therefore, according to the authors, the pandemic probably had an unexpressive impact on the PSD frequencies [19]. Furthermore, in the Saudi Arabia study, depression after stroke was associated with the NIHSS and the degree of dependence evaluated by the mRS [19], as observed in the present study, although in our study the PSD has been evaluated during hospitalization. Although the pandemic could have a significant role in the frequency of mood disorders, the data above demonstrate that this fact was not observed when PSD was evaluated in the acute phase. Nevertheless, the average of the HADS-D values evidenced an increase in the months of highest severity of the COVID-19 pandemic, which denotes a possible increase in the severity of depressive symptoms in these months.

Regarding the associated factors with PSD, the present study elucidated the female sex and anxiety as important variables of PSD during hospitalization. A study conducted in the Middle East demonstrated that the female sex had twice the risk of developing PSD in the acute phase of stroke [20]. Another study carried out in Japan revealed no difference between sex when PSD was evaluated in the subacute phase of the stroke [21]. In contrast, a data collection conducted by Mayman et al. pointed to the female sex as a risk factor when PSD was evaluated 1.5 years after the stroke [22]. Besides, the study above mentioned by Mayman et al. identified the history of anxiety as a risk factor for PSD [22]. A systematic review also evidenced anxiety as a factor associated with PSD in the acute phase of the stroke [23]. Our research about PSD in the acute phase of the stroke is in agreement with the previous literature. The therapy for depressive and anxiety symptoms was not initiated in the acute phase of the stroke, due to the evidence in the literature of no improvement in long-term outcomes after stroke [24,25]. However, these data provide clues respecting which patients we need to spend special attention to during follow-up, aiming at early diagnosis, treatment, and better recovery after stroke.

Other neurological conditions are acknowledged to be associated with depression and have related factors previously described in the literature. Regarding TBI, the female sex was identified as a risk factor for developing depression after TBI [26], as observed in PSD. Furthermore, a history of a psychiatric disorder has also been highlighted as a risk factor for depression after TBI [26]. Regarding epilepsy, a metanalysis by Yang et al. demonstrated female sex and anxiety disorder as risk factors for the development of the depressive disorder in the context of epilepsy [27].

Our research elucidated a correlation between PSD in the acute phase of the ischemic stroke and factors that evaluated stroke severity such as NIHSS, mRS, and stroke area calculation. A German study evaluated a small sample of patients with transient ischemic attack and stroke in the acute phase and elucidated that HADS-D levels were not associated with NIHSS [28]. In contrast, a Ghanaian study evidenced that NIHSS and mRS were associated with PSD [10]. The assessment of the stroke severity by measuring the stroke area was applied a few times in previous studies about PSD. Studies by Nys et al. [29] and Sharpe et al. [30] identified an association between stroke volume and depressive symptoms after stroke. In opposition, a study by Herrmann did not show an association between the lesion volume and depression after stroke [31].

Regarding the relationship between the laterality of the lesion and the development of PSD, there is no consensus in the literature. In contrast, when the lesion topography was evaluated, the frontal lobe was pointed out by many studies as a risk factor for PSD in the acute phase [32] and three-to-six months after stroke [33]. Our study revealed no relationship between the frontal lobe lesion and the development of PSD in the acute phase. Interestingly, we have identified the parietal lobe lesion as a protective factor for the development of PSD. No description of this data was found in the previous literature and the mechanisms related to this unforeseen association require investigation in future studies.

Another unexpected protection factor identified in our research was the previous history of hypertension. Most studies that investigated hypertension and its relationship with PSD did not demonstrate a relationship between both conditions [10,34]. The finding of our study demands exploration in further studies, including data about antihypertensive medication compliance.

The present study has limitations to be considered. This research was conducted in a specialized neurology center, which may lead to a selection bias as it included potentially critically ill patients. Moreover, most of the sample consisted of mild to moderate strokes, therefore data could not be generalized to more severe strokes. Furthermore, the relatively small sample size could have diminished the influence of some variables potentially associated with PSD, such as the frontal lobe lesion. To our knowledge, this is the first cross-sectional research about PSD in the acute phase of the ischemic stroke conducted in the COVID-19 pandemic period.

#### 5. Conclusion

This research evidenced a high prevalence of PSD in the acute phase of ischemic stroke. To our knowledge, this study is the first cross-sectional survey that sought to investigate PSD during the hospitalization of AIS patients in the COVID-19 pandemic. Despite the pandemic could have influenced the PSD profile, our data remained similar to the non-pandemic periods, except for the impact of the period with the highest incidence of COVID-19 on the severity of the HADS-D average. Sex female and PSA during hospitalization were factors associated with PSD in the acute phase. The NIHSS, mRS, and stroke area calculation were correlated with HADS-D levels. These findings are important because highlight the patients at greater risk of developing PSD during hospitalization, demanding special attention for early diagnosis and timely treatment. Furthermore, it is relevant to emphasize that stroke is treated in distinct health care settings, which emphasizes the

b Spearman test was used.

importance of understanding, with detail, this condition to provide information to similar services and countries. In addition, the protective factors identified in this research necessitate further elucidation in future studies.

#### CRediT authorship contribution statement

S. Elias: conception and design of the study, acquisition of data, analysis, and interpretation of data, drafting the article, revising it critically for important intellectual content, final approval of the version to be submitted. M.L. Benevides: conception and design of the study, acquisition of data, analysis, and interpretation of data, drafting the article, revising it critically for important intellectual content, final approval of the version to be submitted. A.L.P. Martins: analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, final approval of the version to be submitted. G.L. Martins: analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, final approval of the version to be submitted. A.B.S.W. Marcos: analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, final approval of the version to be submitted. J.C. Nunes: conception and design of the study, acquisition of data, analysis, and interpretation of data, drafting the article, revising it critically for important intellectual content, final approval of the version to be submitted.

#### Acknowledgements

None.

Declarations of interest

None.

#### References

- [1] World Health Organization WHO. Global Health Observatory data: World Health Statistics 2019. [Internet]. 2019 [Accessed in 2021 Jul 2]. Available in: (htt ps://www.who.int/gho/publications/world\_health\_statistics/2019/en/).
- [2] Global Burden of Disease (GBD) Brazil. Global Burden of Disease data: 2017. [Internet]. 2021 [Accessed in 2021 Jul 2]. Available in: http://svs.aids.gov.br/dantps/centrais-de-conteudos/paineis-de-monitoramento/mortalidade/gbd-brasil/principais-causas/).
- [3] G.K.R. Das J, Post stroke depression: the sequelae of cerebral stroke, Neurosci. Biobehav. Rev. Jul (90) (2018) 104–114, https://doi.org/10.1016/j. neubiorev.2018.04.005. Epub 2018 Apr 12. PMID: 29656030.
- [4] S. Wang, C.X. Wang, N. Zhang, Y.T. Xiang, Y. Yang, Y.Z. Shi, Y.M. Deng, M.F. Zhu, F. Liu, P. Yu, G.S. Ungvari, C.H. Ng, The association between post-stroke depression, aphasia, and physical independence in stroke patients at 3-month follow-up, Front Psychiatry 9 (2018) 374.
- [5] M.L. Hackett, K. Pickles, Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies, Int. J. Stroke 9 (8) (2014) 1017–1025.
- [6] R.F. Villa, F. Ferrari, A. Moretti, Post-stroke depression: mechanisms and pharmacological treatment, Pharm. Ther. 184 (2018) 131–144.
- [7] I. Loubinoux, G. Kronenberg, M. Endres, P. Schumann-Bard, T. Freret, R. K. Filipkowski, L. Kaczmarek, A. Popa-Wagner, Post-stroke depression: mechanisms, translation and therapy, J. Cell Mol. Med. 16 (9) (2012) 1961–1969.
- [8] L. Ayerbe, S. Ayis, C.D. Wolfe, A.G. Rudd, Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis, Br. J. Psychiatry 202 (1) (2013) 14–21, https://doi.org/10.1192/bjp.bp.111.107664.
- [9] H. Schöttke, L. Gerke, R. Düsing, A. Möllmann, Post-stroke depression and functional impairments - a 3-year prospective study, Compr. Psychiatry 99 (May)

- (2020), 152171, https://doi.org/10.1016/j.comppsych.2020.152171. Epub 2020
- [10] F.S. Sarfo, C. Jenkins, A. Singh, M. Owolabi, A. Ojagbemi, N. Adusei, R. Saulson, B. Ovbiagele, Post-stroke depression in Ghana: characteristics and correlates, J. Neurol. Sci. Aug 15 (379) (2017) 261–265, https://doi.org/10.1016/j.jns.2017.06.032. Epub 2017 Jun 20.
- [11] J. Pais-ribeiro, I. Silva, T. Ferreira, A. Martins, R. Meneses, M. Baltar, Validation study of a Portuguese version of the hospital anxiety and depression scale, Psychol. Health Med. 12 (2007) 225–237.
- [12] U. Sagen, T.G. Vik, T. Moum, T. Mørland, A. Finset, T. Dammen, Screening for anxiety and depression after stroke: comparison of the hospital anxiety and depression scale and the montgomery and åsberg depression rating scale, J. Psychosom. Res. 67 (2009) 325–332.
- [13] R.P. Snaith, The hospital anxiety and depression scale, Health Qual. Life Outcomes 1 (2003) 29.
- [14] F. Anna Stern, The hospital anxiety and depression scale, Occup. Med. Volume 64 (Issue 5) (2014) 393–394.
- [15] Machado A.B. et al. Neuroanatomia funcional. 3ª ed. Atheneu; 2013.
- [16] H. Schöttke, C.M. Giabbiconi, Post-stroke depression and post-stroke anxiety: prevalence and predictors, Int Psychogeriatr. 27 (11) (2015) 1805–1812.
- [17] J.H. White, J. Attia, J. Sturm, G. Carter, P. Magin, Predictors of depression and anxiety in community dwelling stroke survivors: a cohort study, Disabil. Rehabil. 36 (23) (2014) 1975–1982.
- [18] F.J. Carod-Artal, D.S. Trizotto, L.F. Coral, C.M. Moreira, Determinants of quality of life in Brazilian stroke survivors, J. Neurol. Sci. 284 (1–2) (2009) 63–68.
- [19] Z.M. Ahmed, M.F. Khalil, A.M. Kohail, I.F. Eldesouky, A. Elkady, A. Shuaib, The prevalence and predictors of post-stroke depression and anxiety during COVID-19 pandemic, J. Stroke Cereb. Dis. 29 (12) (2020), 105315.
- [20] S.S. Wilkins, N. Akhtar, A. Salam, P. Bourke, S. Joseph, M. Santos, A. Shuaib, Acute post stroke depression at a primary stroke center in the Middle East, PLoS One 13 (12) (2018), 0208708, https://doi.org/10.1371/journal.pone.0208708.
- [21] Y. Kaji, K. Hirata, A. Ebata, Characteristics of post-stroke depression in Japanese patients, Neuropsychobiology 53 (3) (2006) 148–152.
- [22] N.A. Mayman, S. Tuhrim, N. Jette, M.S. Dhamoon, L.K. Stein, Sex differences in post-stroke depression in the elderly, J. Stroke Cereb. Dis. 30 (9) (2021), 105948.
- [23] S.E. Kouwenhoven, M. Kirkevold, K. Engedal, H.S. Kim, Depression in acute stroke: prevalence, dominant symptoms and associated factors. A systematic literature review, Disabil. Rehabil. 33 (7) (2011) 539–556.
- [24] O.P. Almeida, G.J. Hankey, A. Ford, C. Etherton-Beer, L. Flicker, M. Hackett, Assessment of fluoxetine in stroke recovery (AFFINITY) trial collaboration. depression outcomes among patients treated with fluoxetine for stroke recovery: the AFFINITY randomized clinical trial, JAMA Neurol. 78 (9) (2021) 1072–1079.
- [25] L.A. Legg, A.S. Rudberg, X. Hua, S. Wu, M.L. Hackett, R. Tilney, et al., Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery, Cochrane Database Syst. Rev. 11 (11) (2021), 009286.
- [26] R. Singh, S. Mason, F. Lecky, J. Dawson, Prevalence of depression after TBI in a prospective cohort: the SHEFBIT study, Brain Inj. 32 (1) (2018) 84–90.
- [27] Y. Yang, M. Yang, Q. Shi, T. Wang, M. Jiang, Risk factors for depression in patients with epilepsy: a meta-analysis, Epilepsy Behav. 106 (2020), 107030.
- [28] H.H.O. Müller, K. Czwalinna, R. Wang, C. Lücke, A.P. Lam, A. Philipsen, J. M. Gschossmann, S. Moeller, Occurence of post-traumatic stress symptoms, anxiety and depression in the acute phase of transient ischemic attack and stroke, Psychiatr. O 92 (3) (2021) 905–915.
- [29] G.M. Nys, M.J. van Zandvoort, H.B. van der Worp, E.H. de Haan, P.L. de Kort, L. J. Kappelle, Early depressive symptoms after stroke: neuropsychological correlates and lesion characteristics, J. Neurol. Sci. 228 (1) (2005) 27–33.
- [30] M. Sharpe, K. Hawton, V. Seagroatt, J. Bamford, A. House, A. Molyneux, et al., Depressive disorders in long-term survivors of stroke: associations with demographic and social factors, functional status, and brain lesion volume, Br. J. Psychiatry 164 (3) (1994) 380–386.
- [31] M. Herrmann, C. Bartels, M. Schumacher, C.W. Wallesch, Poststroke depression. Is there a pathoanatomic correlate for depression in the postacute stage of stroke? Stroke 26 (5) (1995) 850–856.
- [32] N. Metoki, N. Sugawara, J. Hagii, S. Saito, H. Shiroto, T. Tomita, M. Yasujima, K. Okumura, N. Yasui-Furukori, Relationship between the lesion location of acute ischemic stroke and early depressive symptoms in Japanese patients, Ann. Gen. Psychiatry 15 (2016) 12.
- [33] Y.Z. Shi, Y.T. Xiang, S.L. Wu, N. Zhang, J. Zhou, Y. Bai, S. Wang, Y.L. Wang, X. Q. Zhao, G.S. Ungvari, H.F. Chiu, Y.J. Wang, C.X. Wang, The relationship between frontal lobe lesions, course of post-stroke depression, and 1-year prognosis in patients with first-ever ischemic stroke, PLoS One 9 (7) (2014), 100456, https://doi.org/10.1371/journal.pone.0100456.
- [34] G. Meng, X. Ma, L. Li, Y. Tan, X. Liu, X. Liu, Y. Zhao, Predictors of early-onset postischemic stroke depression: a cross-sectional study, BMC Neurol. 17 (1) (2017) 199.